Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds For Type 2 Diabetes
Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds
Boehringer Ingelheim announced that patients and physicians may have several innovative type 2 diabetes treatment alternatives available in the coming years. At its Second International Research & Development Press Conference, Boehringer Ingelheim unveiled a pipeline of unique oral anti-diabetic compounds in phase II and III, establishing the Company in the type 2 diabetes arena. The incidence and prevalence of type 2 diabetes continues to grow globally with someone dying every 10 seconds from diabetes-related causes. At a time when many pharmaceutical companies have been forced to reduce their investment in Research & Development, diabetes is the second new therapeutic field that Boehringer Ingelheim has entered within the past few years. In November 2006, Boehringer Ingelheim announced their cancer drug development programme, which has progressed significantly since then.
"With three new diabetes compounds with novel modes of action in clinical development, it is with great pleasure that we again can report on Research & Development progress at Boehringer Ingelheim," said Dr.Andreas Barner, Vice Chairman of the Board of Managing Directors Boehringer Ingelheim, responsible for Research Development and Medicine. "Boehringer Ingelheim is scientifically, economically and intellectually well prepared to successfully broaden its diabetes pipeline to meet the needs of physicians and their patients."
At Boehringer Ingelheim's largest Research & Development site and the centre of excellence for metabolic diseases in Biberach, Germany, the research teams have been focusing on the discovery and development of oral anti-diabetic treatments targeting new principles, such as the inhibition of DPP-4 (dipeptidyl peptidase-4 inhibitors) and inhibition of SGLT-2 (sodium-dependent glucose transporter-2 inhibitors). These compounds reflect the Company's dedication to harnessing the most advanced science to efficiently control type 2 diabetes and its often fatal consequences.
"Our research into new treatment options for patients with type 2 diabetes began in 2001 and is now bearing fruit. This is particularly important since despite a variety of treatment options available today, patients continue to struggle with tolerability," said Prof.Klaus Dugi, Head Corporate Department, Medical Affairs, Boehringer Ingelheim.
Other news from the department research and development
